Home
ZEPOSIA® (ozanimod) for MS | For HCPs

ZEPOSIA® (ozanimod) for ... Market Share Analysis for August 2026

Discover more about ZEPOSIA® - an oral therapy for your patients with relapsing forms of MS. See full safety and Prescribing Information.

Health > Biotechnology and Pharmaceuticals

Domainzeposiahcp.com

Year Founded--

Employees> 10001

Annual Revenue--

ZEPOSIA® (ozanimod) for MS | For HCPs

ZEPOSIA® (ozanimod) for MS | For HCPs (including company regionals)

zeposiahcp.com

See more website traffic and engagement information

Total visits to ZEPOSIA® (ozanimod) for MS | For HCPs's top domains

Understand ZEPOSIA® (ozanimod) for MS | For HCPs market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

zeposiahcp.com11.3K

See more with Sales Intelligence

Avg. visit duration in ZEPOSIA® (ozanimod) for MS | For HCPs's top domains

Analyze ZEPOSIA® (ozanimod) for MS | For HCPs engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

zeposiahcp.com00:01:22

See more with Sales Intelligence

Avg. pageviews on ZEPOSIA® (ozanimod) for MS | For HCPs's top domains

See how ZEPOSIA® (ozanimod) for MS | For HCPs keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

zeposiahcp.com1.64

See more with Sales Intelligence

ZEPOSIA® (ozanimod) for MS | For HCPs top competitors by domain

Looks like there’s not enough data here

No Data to Display

Top technologies used by ZEPOSIA® (ozanimod) for MS | For HCPs

These are the website technologies, by industry, used by ZEPOSIA® (ozanimod) for MS | For HCPs top domains

Advertising (11)

DoubleClick

Conversion & Analytics (8)

Google Analytics

Audio Video Media (3)

Vimeo

Content Management System (2)

WordPress

More Technologies

7

See all

News & Signals from ZEPOSIA® (ozanimod) for MS | For HCPs

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsZeposia identified as competitor of Gilenya.Zeposia will compete directly with Novartis' fast-selling Gilenya as well as its newer drug Mayzent, which work similarly, and will launch into a shifting market.

NewsZeposia acquired Celgene Corp. on Mar 27th '19.The company announced the approval of Zeposia, which it acquired when it bought Celgene last year.